Citation 19735

HALL,HI: WILLIAMS,JR WL: CHANEY,SG: GILBERT,CJ: HOLBROOK,DJ: MURAOKA,O: KIYOKAWA,H: LEE,KH:. (1985). ANTITUMOR AGENTS 68: EFFECTS OF A SERIES OF HELENALIN DERIVATIVES ON P-388 LYMPHOCYTIC LEUKEMIA NUCLEIC ACID AND PROTEIN SYNTHESIS.. 74(3)

Citation Details

Title	ANTITUMOR AGENTS 68: EFFECTS OF A SERIES OF HELENALIN DERIVATIVES ON P-388 LYMPHOCYTIC LEUKEMIA NUCLEIC ACID AND PROTEIN SYNTHESIS.
Authors	HALL,HI: WILLIAMS,JR WL: CHANEY,SG: GILBERT,CJ: HOLBROOK,DJ: MURAOKA,O: KIYOKAWA,H: LEE,KH:
Year	1985
Volume	74
Issue	3

Summary

Year: 1985

Journal: Unknown

Organisms and Their Experiments (14)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	ACTIVE
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	ACTIVE
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	ACTIVE
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HYMENOXON	INACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HYMENOXON	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HYMENOXON	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,2-CHLORO-2-3-DIHYDRO:	INACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,2-CHLORO-2-3-DIHYDRO:	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	ACTIVE
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	WEAK ACTIVITY
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	ACTIVE
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	ACTIVE
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-CHLORO-2-3-DIHYDRO:	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	PLENOLIN	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	PLENOLIN	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	WEAK ACTIVITY
4	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	ACTIVE
5	RNA SYNTHESIS STIMULATION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PLENOLIN	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,2-3-DIHYDRO:	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY
4	RNA SYNTHESIS STIMULATION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,2-3-DIHYDRO:	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	WEAK ACTIVITY
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	ACTIVE
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN,METHOXY-ETHOXY-METHYL ETHER	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN MALONATE,ETHYL:	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	ACTIVE
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN MALONATE,ETHYL:	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN 3-3-DIMETHYL-ACRYLATE	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	HELENALIN 3-3-DIMETHYL-ACRYLATE	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	WEAK ACTIVITY
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	HELENALIN 3-3-DIMETHYL-ACRYLATE	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MALONIC ACID BIS-(HELENALINYL) ESTER	ACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MALONIC ACID BIS-(HELENALINYL) ESTER	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	ACTIVE
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	WEAK ACTIVITY
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-(HELENALINYL) ESTER	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MALONIC ACID BIS-PLENOLINYL ESTER	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MALONIC ACID BIS-PLENOLINYL ESTER	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	WEAK ACTIVITY
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	INACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	INACTIVE
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MALONIC ACID BIS-PLENOLINYL ESTER	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
4	RNA SYNTHESIS STIMULATION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(2-3-DIHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	WEAK ACTIVITY
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(TETRAHYDRO-HELENALINYL) MALONATE	INACTIVE

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY
4	RNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	INACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	ACTIVE
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	BIS-(HELENALINYL)-HEX-TRANS-ENE-DI-OATE	WEAK ACTIVITY

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ANTITUMOR ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VIVOANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MICROLENIN	ACTIVE
2	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	MICROLENIN	ACTIVE
3	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	ACTIVE
4	RNA SYNTHESIS STIMULATION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	ACTIVE
5	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	WEAK ACTIVITY
6	DNA POLYMERASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	WEAK ACTIVITY
7	PURINE SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	ACTIVE
8	INOSINIC ACID DEHYDROGENASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	ACTIVE
9	DNA POLYMERASE ALPHA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	MICROLENIN	WEAK ACTIVITY

Show SPARQL Queries (1)